- Home
- EFT vs GOSS Comparison
EFT vs GOSS Comparison
Compare EFT & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EFT
- GOSS
- Stock Information
- Founded
- EFT 2004
- GOSS 2015
- Country
- EFT United States
- GOSS United States
- Employees
- EFT N/A
- GOSS N/A
- Industry
- EFT Finance Companies
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- EFT Finance
- GOSS Health Care
- Exchange
- EFT Nasdaq
- GOSS Nasdaq
- Market Cap
- EFT 327.7M
- GOSS 347.8M
- IPO Year
- EFT N/A
- GOSS 2019
- Fundamental
- Price
- EFT $12.08
- GOSS $2.47
- Analyst Decision
- EFT
- GOSS Strong Buy
- Analyst Count
- EFT 0
- GOSS 4
- Target Price
- EFT N/A
- GOSS $8.50
- AVG Volume (30 Days)
- EFT 100.8K
- GOSS 3.1M
- Earning Date
- EFT 01-01-0001
- GOSS 08-05-2025
- Dividend Yield
- EFT 10.63%
- GOSS N/A
- EPS Growth
- EFT N/A
- GOSS N/A
- EPS
- EFT 1.73
- GOSS N/A
- Revenue
- EFT N/A
- GOSS $40,237,000.00
- Revenue This Year
- EFT N/A
- GOSS N/A
- Revenue Next Year
- EFT N/A
- GOSS $30.65
- P/E Ratio
- EFT $7.62
- GOSS N/A
- Revenue Growth
- EFT N/A
- GOSS N/A
- 52 Week Low
- EFT $11.10
- GOSS $0.66
- 52 Week High
- EFT $13.44
- GOSS $2.65
- Technical
- Relative Strength Index (RSI)
- EFT 43.69
- GOSS 68.08
- Support Level
- EFT $12.00
- GOSS $2.38
- Resistance Level
- EFT $12.24
- GOSS $2.65
- Average True Range (ATR)
- EFT 0.08
- GOSS 0.15
- MACD
- EFT 0.01
- GOSS 0.03
- Stochastic Oscillator
- EFT 63.16
- GOSS 76.67
About EFT Eaton Vance Floating Rate Income Trust of Beneficial Interest
Eaton Vance Floating-rate Income Trust is a closed-end management investment company. The company's objective is to provide a high level of current income and its secondary objective is capital appreciation.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.